Syros Pharmaceuticals Garners $40,000,000 New Financing
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=0a68ef48-0664-407b-9876-904a28d39488 - Date
1/13/2016 - Company Name
Syros Pharmaceuticals - Mailing Address
620 Memorial Drive Cambridge, MA 02139 USA - Company Description
Syros Pharmaceuticals is a life sciences company that is focused on treating disease by mapping gene regulatory circuits and modulating the factors that regulate gene expression. Syros has pioneered world-leading gene control research and drug discovery capabilities. - Website
http://www.syros.com - Transaction Type
Venture Equity - Transaction Amount
$40,000,000 - Transaction Round
Undisclosed - Proceeds Purposes
Proceeds from the financing will be used to advance the Company’s pipeline of gene control medicines, including a Phase 2 study of its lead program, SY-1425, which is expected to begin in the first half of 2016 in a genomically defined subset of patients with acute myelogenous leukemia (AML) and myelodysplastic syndromes (MDS). The funds will also be used to further develop the Company’s proprietary gene control platform with the aim of uncovering novel drug targets and biomarkers and developing medicines to treat cancer and other serious diseases. - M&A Terms
- Venture Investor
Deerfield Capital - Venture Investor
Casdin Capital - Venture Investor
Fidelity Management & Research Company - Venture Investor
WuXi PharmaTech - Venture Investor
Polaris Partners - Venture Investor
Redmile Group - Venture Investor
Aisling Capital - Venture Investor
Alexandria Venture Investments
